<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sensei Biotherapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc</link>
<description>Latest news and press releases for Sensei Biotherapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sensei-biotherapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c22878dffbe2df119363.webp</url>
<title>Sensei Biotherapeutics Inc</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc</link>
</image>
<item>
<title>Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Thu, 09 Apr 2026 11:30:00 GMT</pubDate>
<description>BOSTON, April 09, 2026--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16th, 2026 at 12:45 p.m. ET.</description>
</item>
<item>
<title>Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Faeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway $200 million private placement</description>
</item>
<item>
<title>Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>BOSTON--(BUSINESS WIRE)-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Sensei’s Board of Directors</description>
</item>
<item>
<title>Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-announces-acquisition-of-faeth-therapeutics-and-dollar200-million-concurrent-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-announces-acquisition-of-faeth-therapeutics-and-dollar200-million-concurrent-private-placement</guid>
<pubDate>Wed, 18 Feb 2026 13:00:00 GMT</pubDate>
<description>BOSTON, February 18, 2026--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. ("Faeth"), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The acquisition brings Faeth’s lead asset PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, int</description>
</item>
<item>
<title>Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-third-quarter-123000542</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-third-quarter-123000542</guid>
<pubDate>Fri, 14 Nov 2025 12:30:00 GMT</pubDate>
<description>BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter 2025. On October 30, 2025, the Company announced that its Board of Directors determined, after extensive consideration of the Company’s development pipeline and current market conditions, to discontinue development of solners</description>
</item>
<item>
<title>Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-announces-initiation-strategic-130000375</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-announces-initiation-strategic-130000375</guid>
<pubDate>Thu, 30 Oct 2025 13:00:00 GMT</pubDate>
<description>BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that its Board of Directors has determined, after extensive consideration of the Company’s development pipeline and current market conditions, to discontinue development of solnerstotug and initiate a comprehensive review of strategic alternatives aimed at maximiz</description>
</item>
<item>
<title>Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-clinical-results-120000984</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-clinical-results-120000984</guid>
<pubDate>Fri, 17 Oct 2025 12:00:00 GMT</pubDate>
<description>6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings –All clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort –Favorable safety profile with six cases of mild, manageable grade 1 cytokine release syndrome (CRS) across all patients treated to date, all of which occurred in the 15 mg/kg dose cohort –Data support advancement to Phase 2 studies, currently being planned</description>
</item>
<item>
<title>Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-host-virtual-kol-113000629</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-host-virtual-kol-113000629</guid>
<pubDate>Tue, 23 Sep 2025 11:30:00 GMT</pubDate>
<description>BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will host a virtual key opinion leader (KOL) event on Monday, October 20, 2025 at 8:00 AM ET featuring company leadership and Kyriakos Papadopoulos, MD (Co-Director of Clinical Research at START, San Antonio), who will discuss the unmet need and current t</description>
</item>
<item>
<title>Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-participate-h-c-120000786</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-participate-h-c-120000786</guid>
<pubDate>Wed, 03 Sep 2025 12:00:00 GMT</pubDate>
<description>BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025. An on-demand corporate presentation will be available here on Septembe</description>
</item>
<item>
<title>Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-second-quarter-113000529</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-second-quarter-113000529</guid>
<pubDate>Tue, 05 Aug 2025 11:30:00 GMT</pubDate>
<description>- Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter 2025, and provided a corporate update. “The second quarter was a key inflection point for Sensei, as</description>
</item>
<item>
<title>Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-present-clinical-data-113000859</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-present-clinical-data-113000859</guid>
<pubDate>Wed, 30 Jul 2025 11:30:00 GMT</pubDate>
<description>BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug alone and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, will be presented in a mini oral session at the European Society for Medical Oncology (ESMO)</description>
</item>
<item>
<title>Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-announces-1-20-113000195</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-announces-1-20-113000195</guid>
<pubDate>Fri, 13 Jun 2025 11:30:00 GMT</pubDate>
<description>BOSTON, June 13, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will implement a 1-for-20 reverse stock split of its issued and outstanding shares of common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Comp</description>
</item>
<item>
<title>Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-first-quarter-113000849</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-first-quarter-113000849</guid>
<pubDate>Tue, 06 May 2025 11:30:00 GMT</pubDate>
<description>- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter 2025, and provided corporate updates. “T</description>
</item>
<item>
<title>Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-participate-canaccord-genuity-113000652</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-participate-canaccord-genuity-113000652</guid>
<pubDate>Wed, 02 Apr 2025 11:30:00 GMT</pubDate>
<description>BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET. About Sensei Biotherapeuti</description>
</item>
<item>
<title>Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-full-2024-113000303</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-full-2024-113000303</guid>
<pubDate>Fri, 28 Mar 2025 11:30:00 GMT</pubDate>
<description>- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population - - Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile - - Achieved target enrollment in dose expansion cohort; full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage</description>
</item>
<item>
<title>Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-favorable-preliminary-200500147</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-favorable-preliminary-200500147</guid>
<pubDate>Thu, 27 Mar 2025 20:05:00 GMT</pubDate>
<description>– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a Merkel Cell Carcinoma (MCC) patient and two partial responses (PR), including one in a second MCC patient and one in a microsatellite instability-high (MSI-H) Colorectal Cancer (CRC) patient, all of whom were previously treated with and progressed on immunotherapy – – All PD-(L)1 re</description>
</item>
<item>
<title>Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-to-participate-in-oppenheimers-35th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-to-participate-in-oppenheimers-35th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Tue, 04 Feb 2025 05:00:00 GMT</pubDate>
<description>BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and</description>
</item>
<item>
<title>Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-provides-corporate-update-and-highlights-key-upcoming-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-provides-corporate-update-and-highlights-key-upcoming-milestones</guid>
<pubDate>Wed, 08 Jan 2025 05:00:00 GMT</pubDate>
<description>- Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08,</description>
</item>
<item>
<title>Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference</guid>
<pubDate>Wed, 27 Nov 2024 05:00:00 GMT</pubDate>
<description>BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and</description>
</item>
<item>
<title>Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-third-quarter-2024-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/sensei-biotherapeutics-inc/news/sensei-biotherapeutics-reports-third-quarter-2024-financial-results-and-recent-business-highlights</guid>
<pubDate>Thu, 14 Nov 2024 05:00:00 GMT</pubDate>
<description>- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the</description>
</item>
</channel>
</rss>